Cargando…

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab

Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanoue, Kenro, Tamura, Shingo, Kusaba, Hitoshi, Shinohara, Yudai, Ito, Mamoru, Tsuchihashi, Kenji, Shirakawa, Tsuyoshi, Otsuka, Taiga, Ohmura, Hirofumi, Isobe, Taichi, Ariyama, Hiroshi, Koreishi, Sakuya, Matsushita, Yuzo, Shimokawa, Hozumi, Tanaka, Risa, Mitsugi, Kenji, Akashi, Koichi, Baba, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854616/
https://www.ncbi.nlm.nih.gov/pubmed/33531609
http://dx.doi.org/10.1038/s41598-021-82448-1
_version_ 1783646117578145792
author Tanoue, Kenro
Tamura, Shingo
Kusaba, Hitoshi
Shinohara, Yudai
Ito, Mamoru
Tsuchihashi, Kenji
Shirakawa, Tsuyoshi
Otsuka, Taiga
Ohmura, Hirofumi
Isobe, Taichi
Ariyama, Hiroshi
Koreishi, Sakuya
Matsushita, Yuzo
Shimokawa, Hozumi
Tanaka, Risa
Mitsugi, Kenji
Akashi, Koichi
Baba, Eishi
author_facet Tanoue, Kenro
Tamura, Shingo
Kusaba, Hitoshi
Shinohara, Yudai
Ito, Mamoru
Tsuchihashi, Kenji
Shirakawa, Tsuyoshi
Otsuka, Taiga
Ohmura, Hirofumi
Isobe, Taichi
Ariyama, Hiroshi
Koreishi, Sakuya
Matsushita, Yuzo
Shimokawa, Hozumi
Tanaka, Risa
Mitsugi, Kenji
Akashi, Koichi
Baba, Eishi
author_sort Tanoue, Kenro
collection PubMed
description Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42–3.47; p < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38–2.80; p < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.
format Online
Article
Text
id pubmed-7854616
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78546162021-02-03 Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab Tanoue, Kenro Tamura, Shingo Kusaba, Hitoshi Shinohara, Yudai Ito, Mamoru Tsuchihashi, Kenji Shirakawa, Tsuyoshi Otsuka, Taiga Ohmura, Hirofumi Isobe, Taichi Ariyama, Hiroshi Koreishi, Sakuya Matsushita, Yuzo Shimokawa, Hozumi Tanaka, Risa Mitsugi, Kenji Akashi, Koichi Baba, Eishi Sci Rep Article Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42–3.47; p < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38–2.80; p < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab. Nature Publishing Group UK 2021-02-02 /pmc/articles/PMC7854616/ /pubmed/33531609 http://dx.doi.org/10.1038/s41598-021-82448-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Tanoue, Kenro
Tamura, Shingo
Kusaba, Hitoshi
Shinohara, Yudai
Ito, Mamoru
Tsuchihashi, Kenji
Shirakawa, Tsuyoshi
Otsuka, Taiga
Ohmura, Hirofumi
Isobe, Taichi
Ariyama, Hiroshi
Koreishi, Sakuya
Matsushita, Yuzo
Shimokawa, Hozumi
Tanaka, Risa
Mitsugi, Kenji
Akashi, Koichi
Baba, Eishi
Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
title Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
title_full Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
title_fullStr Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
title_full_unstemmed Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
title_short Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
title_sort predictive impact of c-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854616/
https://www.ncbi.nlm.nih.gov/pubmed/33531609
http://dx.doi.org/10.1038/s41598-021-82448-1
work_keys_str_mv AT tanouekenro predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT tamurashingo predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT kusabahitoshi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT shinoharayudai predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT itomamoru predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT tsuchihashikenji predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT shirakawatsuyoshi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT otsukataiga predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT ohmurahirofumi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT isobetaichi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT ariyamahiroshi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT koreishisakuya predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT matsushitayuzo predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT shimokawahozumi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT tanakarisa predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT mitsugikenji predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT akashikoichi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab
AT babaeishi predictiveimpactofcreactiveproteintoalbuminratioforrecurrentormetastaticheadandnecksquamouscellcarcinomareceivingnivolumab